ATE457166T1 - Orale zusammensetzungen zur behandlung von diabetes - Google Patents
Orale zusammensetzungen zur behandlung von diabetesInfo
- Publication number
- ATE457166T1 ATE457166T1 AT03817619T AT03817619T ATE457166T1 AT E457166 T1 ATE457166 T1 AT E457166T1 AT 03817619 T AT03817619 T AT 03817619T AT 03817619 T AT03817619 T AT 03817619T AT E457166 T1 ATE457166 T1 AT E457166T1
- Authority
- AT
- Austria
- Prior art keywords
- oral compositions
- treating diabetes
- therapeutic agent
- better
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2003/002949 WO2005009412A1 (en) | 2003-07-24 | 2003-07-24 | Oral compositions for treatment of diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE457166T1 true ATE457166T1 (de) | 2010-02-15 |
Family
ID=34090434
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03817619T ATE457166T1 (de) | 2003-07-24 | 2003-07-24 | Orale zusammensetzungen zur behandlung von diabetes |
Country Status (9)
Country | Link |
---|---|
US (1) | US20060134206A1 (de) |
EP (1) | EP1558220B1 (de) |
AT (1) | ATE457166T1 (de) |
AU (1) | AU2003249492A1 (de) |
CA (1) | CA2536111A1 (de) |
DE (1) | DE60331236D1 (de) |
ES (1) | ES2340997T3 (de) |
PT (1) | PT1558220E (de) |
WO (1) | WO2005009412A1 (de) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
EP1523979A1 (de) * | 2003-10-13 | 2005-04-20 | Wyeth | Darreichungsform mit verlängerter Freisetzung |
US20090098201A1 (en) * | 2004-06-28 | 2009-04-16 | Bio Intellectual Property Services (Bio Ips) Llc | Composition and Method for Treatment and Prevention of Atherosclerosis |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
WO2006123213A1 (en) * | 2005-05-18 | 2006-11-23 | Ranbaxy Laboratories Limited | Modified release formulations of gliclazide |
DE102005031577A1 (de) * | 2005-07-06 | 2007-01-11 | Bayer Healthcare Ag | Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten |
WO2007093021A1 (en) * | 2006-02-17 | 2007-08-23 | Bayer Healthcare Ag | Package, or drug kit, or drug smooth administration presentation for the treatment of hypertension, angina and others kinds of cardiovascular diseases. |
MX2008014024A (es) | 2006-05-04 | 2008-11-14 | Boehringer Ingelheim Int | Formas poliformas. |
EP1852108A1 (de) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | Zusammensetzungen von DPP-IV-Inhibitoren |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
WO2008001311A2 (en) * | 2006-06-26 | 2008-01-03 | Ranbaxy Laboratories Limited | Pharmaceutical composition containing fixed dose combination of atenolol with isosorbide mononitrate |
PE20080907A1 (es) * | 2006-08-31 | 2008-08-22 | Novartis Ag | Sistema de suministro de farmaco oral gastro-retentivo de liberacion extendida para valsartan |
WO2008062470A2 (en) * | 2006-10-19 | 2008-05-29 | Torrent Pharmaceuticals Limited | Stabilized controlled release dosage form of gliclazide |
MY154869A (en) * | 2007-01-16 | 2015-08-14 | Ipintl Llc | Composition for treating metabolic syndrome |
DK2152078T3 (da) | 2007-04-27 | 2021-02-08 | Cydex Pharmaceuticals Inc | Formuleringer indeholdende clopidogrel og sulfoalkylethercyclodextrin og anvendelsesfremgangsmåder |
WO2009120844A2 (en) * | 2008-03-26 | 2009-10-01 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical compositions comprising insulin sensitizer and insulin secretagogue |
PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
CA2666036C (en) * | 2008-05-16 | 2017-09-12 | Chien-Hung Chen | Novel compositions and methods for treating hyperproliferative diseases |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
EP3187182B1 (de) | 2008-09-02 | 2021-03-03 | Amarin Pharmaceuticals Ireland Limited | Pharmazeutische zusammensetzungen mit eicosapentaensäure und nikotinsäure und verfahren zur verwendung davon |
TW201014850A (en) * | 2008-09-25 | 2010-04-16 | Takeda Pharmaceutical | Solid pharmaceutical composition |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
UY32177A (es) * | 2008-10-16 | 2010-05-31 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético |
EP2181705A1 (de) | 2008-10-31 | 2010-05-05 | Disphar International B.V. | Gliclazid-Formulierung mit verlängerter Freisetzung |
DE102008059206A1 (de) | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum |
CN107011345A (zh) | 2008-12-23 | 2017-08-04 | 勃林格殷格翰国际有限公司 | 有机化合物的盐形式 |
AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
WO2010107702A1 (en) * | 2009-03-16 | 2010-09-23 | Ipintl, Llc | Treating alzheimer's disease and osteoporosis and reducing aging |
RU2624506C2 (ru) | 2009-04-29 | 2017-07-04 | АМАРИН КОРПОРЕЙШН ПиЭлСи | Фармацевтические композиции, содержащие ера и сердечно-сосудистое средство, и способы их применения |
EP2424356B1 (de) | 2009-04-29 | 2017-08-23 | Amarin Pharmaceuticals Ireland Limited | Stabile pharmazeutische zusammensetzung und verwendungsverfahren dafür |
DK3100728T3 (da) | 2009-05-13 | 2020-02-17 | Cydex Pharmaceuticals Inc | Farmaceutiske sammensætninger omfattende prasugrel og cyclodextrin-derivativ og fremgangsmåder til fremstilling og brug af samme |
EP3698781A1 (de) | 2009-06-15 | 2020-08-26 | Amarin Pharmaceuticals Ireland Limited | Zusammensetzungen mit eicosapentaensäure zur behandlung von myokardinfarktionen bei patienten mit gleichzeitiger statin-therapie |
RU2012116079A (ru) | 2009-09-23 | 2013-10-27 | АМАРИН КОРПОРЕЙШН ПиЭлСи | Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина и способы ее применения |
EP3646859A1 (de) | 2009-11-27 | 2020-05-06 | Boehringer Ingelheim International GmbH | Behandlung von genotypisierten diabetes-patienten mit dpp-iv-hemmern wie etwa linagliptin |
US9367371B2 (en) * | 2010-02-05 | 2016-06-14 | Paypal, Inc. | Widget framework, real-time service orchestration, and real-time resource aggregation |
AU2011249722B2 (en) | 2010-05-05 | 2015-09-17 | Boehringer Ingelheim International Gmbh | Combination therapy |
AR084698A1 (es) * | 2010-06-22 | 2013-06-05 | Twi Pharmaceuticals Inc | Composiciones de liberacion controlada con reducido efecto de alimentos, reducida interaccion entre farmaco y los alimentos |
BR112012032579B1 (pt) | 2010-06-24 | 2021-05-11 | Boehringer Ingelheim International Gmbh | uso de linagliptina e composição farmacêutica compreendendo linagliptina e insulina basal de longa duração |
JP2013538807A (ja) * | 2010-09-01 | 2013-10-17 | ルピン・リミテッド | メトホルミンおよびピオグリタゾンを含む医薬組成物 |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
NZ744990A (en) | 2010-11-29 | 2019-10-25 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
HUE043540T2 (hu) | 2011-07-15 | 2019-08-28 | Boehringer Ingelheim Int | Szubsztituált dimer kinazolin-származék, elõállítása, valamint alkalmazása 1-es és 2-es típusú cukorbetegség kezelésére szolgáló gyógyászati készítményekben |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
EP2775837A4 (de) | 2011-11-07 | 2015-10-28 | Amarin Pharmaceuticals Ie Ltd | Verfahren zur behandlung von hypertriglyceridämie |
JP6307442B2 (ja) | 2012-01-06 | 2018-04-04 | アマリン ファーマシューティカルス アイルランド リミテッド | 対象の高感度(hs−crp)のレベルを低下させる組成物および方法 |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
SG11201406363VA (en) | 2012-05-07 | 2014-11-27 | Bayer Pharma AG | Process for manufacturing a pharmaceutical dosage form comprising nifedipine and candesartan cilexetil |
EP3685839A1 (de) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin zur verwendung in der behandlung von albuminuria und nierenbedingten erkrankungen |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
PT3363433T (pt) | 2012-06-29 | 2021-02-15 | Amarin Pharmaceuticals Ie Ltd | Métodos de redução do risco de um episódio cardiovascular num indivíduo em terapia com estatina utilizando éster etílico do ácido eicosapentaenoico |
WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
ES2950384T3 (es) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Uso médico de un inhibidor de DPP-4 |
AU2015243353A1 (en) * | 2014-04-08 | 2016-10-13 | Neurovive Pharmaceutical Ab | Succinate prodrugs for use in the treatment of lactic acidosis or drug-induced side-effects due to complex i-related impairment of mitochondrial oxidative phosphorylation |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
US9839644B2 (en) | 2014-09-09 | 2017-12-12 | ARKAY Therapeutics, LLC | Formulations and methods for treatment of metabolic syndrome |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
BR112018072401A2 (pt) | 2016-06-10 | 2019-02-19 | Boehringer Ingelheim International Gmbh | combinações de linagliptina e metformina |
WO2018213663A1 (en) | 2017-05-19 | 2018-11-22 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
SG11202102872QA (en) | 2018-09-24 | 2021-04-29 | Amarin Pharmaceuticals Ie Ltd | Methods of reducing the risk of cardiovascular events in a subject |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6011049A (en) * | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
EP1039890B1 (de) * | 1997-12-08 | 2004-03-17 | Bristol-Myers Squibb Company | Neue metformin salze und verfahren |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US6586438B2 (en) * | 1999-11-03 | 2003-07-01 | Bristol-Myers Squibb Co. | Antidiabetic formulation and method |
WO2001082916A2 (en) * | 2000-05-03 | 2001-11-08 | Tularik Inc. | Combination therapeutic compositions and methods of use |
HUP0002628A2 (en) * | 2000-07-14 | 2002-06-29 | Keri Pharma Kft | Pharmaceutical combinations for treating diabetes |
US6491950B1 (en) * | 2000-08-07 | 2002-12-10 | Kos Pharmaceuticals, Inc. | Controlled release pharmaceutical composition |
CA2423141A1 (en) * | 2000-09-27 | 2002-04-04 | Merck & Co., Inc. | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
BR0115055A (pt) * | 2000-10-30 | 2003-12-30 | Ortho Mcneil Pharm Inc | Terapia de combinação compreendendo agentes anticonvulsantes e antidiabéticos |
US6689385B2 (en) * | 2000-11-03 | 2004-02-10 | Chronorx Llc | Formulations for the treatment of insulin resistance and type 2 diabetes mellitus |
US6693094B2 (en) * | 2001-03-22 | 2004-02-17 | Chrono Rx Llc | Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus |
FR2825023B1 (fr) * | 2001-05-23 | 2005-04-15 | Flamel Tech Sa | Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif |
EP1515701B1 (de) * | 2002-06-17 | 2014-09-17 | Inventia Healthcare Private Limited | Verfahren zur herstellung von mehrschichtigen tabletten die thiazolidinedione und biguanide enthalten |
-
2003
- 2003-07-24 US US10/533,670 patent/US20060134206A1/en not_active Abandoned
- 2003-07-24 PT PT03817619T patent/PT1558220E/pt unknown
- 2003-07-24 AU AU2003249492A patent/AU2003249492A1/en not_active Abandoned
- 2003-07-24 CA CA002536111A patent/CA2536111A1/en not_active Abandoned
- 2003-07-24 EP EP03817619A patent/EP1558220B1/de not_active Expired - Lifetime
- 2003-07-24 ES ES03817619T patent/ES2340997T3/es not_active Expired - Lifetime
- 2003-07-24 AT AT03817619T patent/ATE457166T1/de not_active IP Right Cessation
- 2003-07-24 WO PCT/IB2003/002949 patent/WO2005009412A1/en active Application Filing
- 2003-07-24 DE DE60331236T patent/DE60331236D1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US20060134206A1 (en) | 2006-06-22 |
EP1558220A4 (de) | 2006-07-12 |
EP1558220A1 (de) | 2005-08-03 |
CA2536111A1 (en) | 2005-02-03 |
PT1558220E (pt) | 2010-03-12 |
EP1558220B1 (de) | 2010-02-10 |
DE60331236D1 (de) | 2010-03-25 |
WO2005009412A1 (en) | 2005-02-03 |
AU2003249492A1 (en) | 2005-02-14 |
ES2340997T3 (es) | 2010-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE457166T1 (de) | Orale zusammensetzungen zur behandlung von diabetes | |
DE60117043D1 (de) | Behandlung von mukositis | |
NO20074999L (no) | Metode og preparat for behandling av perifere vaskulaere sykdommer | |
UY26130A1 (es) | Compuestos para tratar la obesidad | |
DK1970059T3 (da) | Lægemiddel med calciumdobesilat til behandling og profylakse af senelidelser | |
BR0116370A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente. | |
MA28935B1 (fr) | Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite | |
WO2004043341A3 (en) | Treatment for hemorrhagic shock | |
BR0317747A (pt) | Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave | |
MXPA05008649A (es) | Terapia de combinacion para el tratamiento de desordenes inmunoinflamatorios. | |
EA200601837A1 (ru) | Бензоксазины для лечения заболеваний дыхательных путей | |
CY1108932T1 (el) | Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων | |
EA200702212A1 (ru) | Способ лечения или профилактики разрушения кости или остеопороза | |
BR0316723A (pt) | Derivados de anilinopirazol úteis para o tratamento de diabetes | |
CY1110369T1 (el) | Νεος συνεργιστικος συνδυασμος ο οποιος περιεχει ροφλουμιλαστη και φορμοτερολη | |
TW200719903A (en) | Compositions for the treatment of neoplasms | |
BR0310061A (pt) | Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições | |
DE602004031631D1 (de) | Verwendung von betain zur behandlung von claudicatio intermittens | |
IL170519A (en) | Use of fenofibrate or pharmaceutically acceptable salt thereof, orlistat and pharmaceutically acceptable carrier in the manufacture of medicaments for the treatment of obesity and pharmaceutical compositions containing them | |
TW200511999A (en) | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone | |
ATE491442T1 (de) | 1-phenyl-2- dimethylaminomethylcyclohexanverbindungen zur therapie von depressiven symptomatiken, schmerz und inkontinenz | |
ATE265225T1 (de) | Pharmazeutische präparation, enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen | |
BR0311180A (pt) | Métodos para o tratamento de doenças e condições respiratórias utilizando um inibidor seletivo da inos | |
DE50214008D1 (de) | Arzneimittel zur behandlung von tumoren und deren metastasen unter verwendung eines bindemoleküls gegen das bone-sialoprotein | |
ATE399544T1 (de) | Synergistische zusammensetzung enthaltend roflumilast und (r,r)-formoterol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |